Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, shared her recent article on X:
“We looked at trends in dose escalation for definitive chemoRT in esophagus cancer from 2006-2016.
By that point, 50.4 already most common dose, but 56% of cervical esophagus SCC received >50.4 Gy.
Would be interesting to see practice patterns now post ARTDECO, PRODIGE 26, etc.”
Patterns of Dose Escalation Among Patients With Esophageal Cancer Undergoing Definitive Radiation Therapy: 2006-2016.
Authors: Elizabeth R Zhang-Velten, et al.
